نتایج جستجو برای: روش esas
تعداد نتایج: 372006 فیلتر نتایج به سال:
The ESAS will provide an opportunity to compare and contrast treatment provision with colleagues who achieve similar levels of quality outcome and there may be differences, for example, in treatment duration or levels of decalcification. All this can be achieved using the ESAS database and simple analyses. Achieving recognition in providing high quality care on your routine cases can compliment...
Epoetin beta belongs to the class of erythropoiesis-stimulating agents (ESAs) that are currently available to treat anemic patients receiving chemotherapy. Chemotherapy-induced anemia affects a high percentage of cancer patients and, due to its negative effects on disease outcome and the patient's quality of life, should be treated when first diagnosed. Initial trials with ESAs have shown effic...
Based on five-level rate-equation theory, we develop the laser-pulse-duration dependence of two-photon-absorption-induced singlet and triplet excited-state absorptions (ESAs). We present analytical expressions for the effective three-photon absorption coefficients caused by both singlet and triplet ESAs under the pulsed excitation on time scales from femtoseconds to microseconds. We demonstrate...
Chronic noncancer pain is a prevalent problem associated with poor quality of life. While symptom burden is frequently mentioned in the literature and clinical settings, this research highlights the considerable negative impact of chronic pain on the individual. The 15D, a measure of health-related quality of life (HRQOL), is a user-friendly tool with good psychometric properties. Using a modif...
Given the apparent presence of erythropoietin receptors (EPORs) in cancer tissues, questions have been raised about the possible influence of erythropoiesis-stimulating agents (ESAs) on tumor growth and proliferation. Preclinical studies of ESAs have shown no greater tumor proliferation in cell lines and no adverse effect on treatment outcomes in animal models. Furthermore, it appears that the ...
Anemia of renal disease is common and is associated with significant morbidity and death. It is mainly caused by a decrease in erythropoietin production in the kidneys and can be partially corrected with erythropoiesis-stimulating agents (ESAs). However, randomized controlled trials have shown that using ESAs to target normal hemoglobin levels can be harmful, and have called into question any b...
OBJECTIVE Anemia and secondary hyperparathyroidism are the two most common complications associated with chronic kidney disease. Erythropoiesis-stimulating agents (ESAs) are widely used in the management of anemia in hemodialysis patients. A reverse correlation has been established between hyperparathyroidism and hemoglobin levels. The aim of this retrospective study is to evaluate the relation...
Since 2010, the European Medicines Agency (EMA) has provided access to clinical study reports (CSRs). We requested CSRs for randomized controlled trials (RCTs) of erythropoiesis-stimulating agents (ESAs) in cancer patients from EMA and identified RCT publications with literature searches. We assessed CSR availability and completeness, the impact of unreported and unpublished data obtained from ...
OBJECTIVE Ferumoxytol has demonstrated superior efficacy compared with oral iron in treating iron deficiency anemia in chronic kidney disease (CKD) patients. However, an economic evaluation of ferumoxytol has not been conducted. The aim of this study was to analyze the cost-effectiveness of treating iron deficiency anemia in adult non-dialysis-dependent CKD patients with ferumoxytol as compared...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید